AZD-3289

• UNSPSC Description:

  AZD-3289 is a potent BACE1 inhibitor with potential Alzheimer's disease inhibitory activity. The application of AZD-3289 is intended to slow the pathological progression of Alzheimer's disease by inhibiting the production of β-amyloid protein. The development of AZD-3289 responds to the need to reduce neurodegenerative changes associated with Alzheimer's disease. As a BACE1 inhibitor, AZD-3289 can effectively reduce the accumulation of β-amyloid peptide in the brain, which may improve cognitive function[1].

• Target Antigen:

  Endogenous Metabolite

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/azd-3289.html

• Smiles:

  NC1=N[C@@](C2=CC(C3=CN=CN=C3)=C(C=C2)F)(C4=CC=NC(C(F)(F)F)=C4)C5=CC=CC(F)=C51

• Molecular Weight:

  467.39

• References & Citations:

  [1]Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugs

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1227163-49-6